Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human single-dose OMS1029 study in healthy volunteers
NL-OMON53550Phase 1Completed
- Sponsor
- Omeros Corporation
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of OMS1029 in IgA nephropathy (IgAN) and autoimmune disease (6 arms), sponsored by Omeros Corporation. Primary endpoint: Safety and tolerability. Started Jul 2022; status: completed.
02
Drugs
OMS1029
03
Conditions
IgA nephropathy (IgAN)autoimmune disease
Beyond the preview
Go deeper on NL-OMON53550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53550.